Alps Group Inc.

ALPS Healthcare Biotechnology

Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.

EPS
−609.4%
Free cash flow
−26.5%

Quarter to September 2025, against a year earlier

0.33 0.02 +6.45%
Market cap
$52.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
−1.64
Dividend safety
n/a
Older periods Mar '25 Jun '25 Sep '25 Mar '26
ROE

+8 more TTM periods

14.32% 19.73% 25.50% —
ROA
(8.18%) (12.10%) (17.24%) 0.00%
ROIC
0.00% 0.00% 0.00% —
Return on Tangible Assets
19.75% 25.68% 31.93% —
Free Cash Flow per Share
(0.38) (0.26) (0.28) —
Free Cash Flow
(1.31) (0.91) (0.96) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026